Eden News

Eden is pleased to announce that it has been highly commended in two categories in the 2019 Agrow Awards.

Sustaine™ was highly commended in the Best New Formulation Category. 

Sustaine™ is a novel, patented encapsulation solution for a wide range of currently registered agrochemicals. Sustaine™ capsules are naturally sourced biodegradable micro-spheres producing stablished aqueous emulsions which, are easy to mix and apply, safer to the environment and have reduced phytotoxicity. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem.

Mevalone™ was highly commended in the Best New Biopesticide category. 

Mevalone™ is a unique biofungicide based on natural plant chemistry, successfully utilised by growers as a valuable part of their crop protection programmes. Developed by Eden Research plc and distributed via commercial partners across Europe and Kenya, Mevalone provides an invaluable tool to tackle Botrytis cinerea. The antifungal activity of a combination of three plant terpenes is harnessed by Eden’s patented microencapsulation technology, Sustaine™. Solvent free, residue exempt, efficacious and price competitive, Mevalone represents a significant step forward in the development of new and reliable, biological crop protection technology.

https://agribusinessintelligence.informa.com/events-and-webinars/events/crop-science-forum-and-awards

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural, plastic- free microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces that Sean Smith, CEO, has today purchased 114,313 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at a price of 8.3 pence.

Following this purchase, Mr Smith holds 547,706 Ordinary Shares representing approximately 0.26 per cent. of the Company's issued share capital.

For full details please click here.

Eden is pleased to announce that its commercial partner, Eastman Chemical Company ("Eastman"), has received full authorisation for Eden's nematicide formulation, marketed as Cedroz^TM by Eastman, from the Belgian Ministry of Agriculture.

Cedroz is an innovative and natural solution designed to fight nematodes, a pest that is known to cause severe damage to crops globally for both open field and greenhouse growers, resulting in potential yield losses and increasing farmers' costs. Belgium has authorised the use of Cedroz on a wide range of crops, including cucumbers, courgettes, melons, aubergine, peppers, tomatoes and strawberries.

Whilst the market opportunities for Cedroz in Belgium are smaller than in other markets such as Italy and Spain, this is the first full authorisation in the EU following the initial authorisation of Cedroz by the Rapporteur Member State, Malta, earlier this year. This is also the first authorisation of any Eden formulated product for use in greenhouse applications in Europe.

In line with consumer demand and a regulatory push for products that support sustainable agriculture and zero pesticide residues, Cedroz is an attractive alternative for farmers looking to fight nematodes in an environmentally friendly way. Unlike many other products, Cedroz is residue-free and has a zero-day pre-harvest interval, thereby allowing applications right up to harvest, if required.

Sean Smith, Chief Executive Officer of Eden, said: "There are multiple, significant opportunities for the use of Cedroz in greenhouse applications which means that the authorisation in Belgium, where the primary use will be in greenhouses, is a very good starting point for authorisations to come in other EU Member States.

In addition, authorisations which are due to follow in other Member States will also include outdoor application where the market opportunities are potentially even greater."

For further detail please click here.

Eden Research plc (AIM: EDEN), the AIM-listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces its interim results for the six months ended 30 June 2019. 

Financial highlights

• Revenue for the period of £0.58m (H1 2018: £0.68m)
• Product sales £0.45m (H1 2018: £0.68m) 
• Upfront and milestone payments of £0.13m (H1 2018: £nil)
• Operating loss for the period reduced to £0.63m (H1 2018: £0.93m) 
• Cash and cash equivalents of £1.36m (H1 2018: £2.62m)

Business & Operational highlights  

• Eden's nematicide formulation, Cedroz, has been approved by the zonal rapporteur member state for use in the southern and indoor EU regulatory zones. Cedroz is an innovative and sustainable solution designed to fight plant parasitic nematodes, pests that are known to cause severe damage to crops globally in both open field and greenhouse growing environments, resulting in significant yield losses and increasing growers' costs. 
• Emergency use authorisation granted in Italy for the treatment of nematodes on tomatoes and a range of additional crops, leading to the first commercial sales of Cedroz.
• Emergency use authorisation has been granted for the use of Mevalone to combat post harvest storage disease on apples in France.  Mevalone is a terpene-based fungicide that initially targeted Botrytis, a widespread fungal disease that causes grey mould on many fruits and vegetables, leading to the rapid loss of commercially valuable crops.  Treatment of apples for post harvest diseases represents an entirely new market for Mevalone.
• Appointment of Rob Cannings as Commercial Director and Felicity Lenyk as Product and Market Manager.

The full report can be downloaded here.

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its commercial partner, Sumi Agro France ("Sumi Agro"), has received a 120 day "emergency use" authorisation for Eden's fungicide, Mevalone, from the French authorities for the treatment of storage diseases on apples. Such "emergency" authorisations are allowed by EU member states when local regulatory authorities judge that they are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives.

Sumi Agro has been selling Mevalone in France since receiving approval for the sale and use of Mevalone for the treatment of botrytis on table and wine grapes in January 2017. This 120-day derogation represents the first authorisation for the use of Mevalone on apples and for the treatment of post-harvest storage diseases. Under this 120-day derogation, Sumi Agro will sell Mevalone to apple producers who will apply Mevalone just prior to harvest. France is one of the top ten producers of apples globally and is the third largest producer in Europe. France is also the fifth largest exporter of apples globally by value.

Mevalone offer growers tremendous advantages by providing efficacy against important crop diseases with active ingredients that are exempt from residue limits and the ability to apply the product just prior to harvest. The benefits of Mevalone are further expanded in this new use as growers are now able to extend the shelf-life of apples and help to reduce food waste and cost in the supply chain. Regulatory authorisation of Mevalone for this use in France and other territories remains subject to full regulatory approval.

Sean Smith, Chief Executive Officer of Eden, said: "This is excellent news supporting the further growth of Mevalone sales as it represents a major new use on an important crop for the treatment of diseases that affect the shelf life of apples. Extending the shelf life of any produce is an impactful way of helping to reduce food chain costs and food waste.

“Whist this derogation is valid until the 21st of November 2019, it is a useful illustration of the importance placed by the authorities on the introduction of new, sustainable crop protection products that meet consumer demand for safe foods that are free from pesticide residues. We are working actively with Sumi Agro to support the full authorisation of Mevalone for use in the treatment of pome fruit storage disease, and we believe that this is achievable in the foreseeable future.”

Antoine Meyer, President of Sumi Agro France, said: "For the Sumi Agro France team, this emergency use is another important opportunity to promote Mevalone to growers and to better serve a modern and evolving agriculture responding fully to the needs of society. It represents also the strong and constructive cooperation between Eden and Sumi Agro France vis-à-vis influencers and political and administrative authorities."

For further information contact:

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

Mevalone has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania and Portugal.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce the appointment of Robert (“Rob”) Cannings to the new role of Commercial Director, with effect from 12 June 2019.

For the last ten years, Rob has worked in an entrepreneurial environment at the cutting edge of the agricultural biologicals industry and, prior to that, in key positions with mainstream conventional agrochemicals. With this extensive knowledge, Rob has been effective in developing strategies and market positioning for new conventional and biological products and using this to prioritise the development and commercialisation of new crop protection products globally.

Rob has been Global Product Manager for Chemtura, AgraQuest, and Bayer CropScience where he created global growth and pricing strategies for conventional and biological products and where he was instrumental in the sale of AgraQuest to Bayer for more than $425m.  Most recently, Rob served as Commercial Director at Plant Health Care with responsibility for Europe, the Middle East, Africa and Asia.

Sean Smith, Chief Executive Officer of Eden, said: “We are pleased to welcome Rob to the team at Eden. Rob’s detailed understanding of the conventional pesticide and biocontrol products markets globally will be a key asset for the company as it works towards delivering on its ambitious growth plans.  His hands-on experience with the entire process from research and development through to product commercialisation, marketing and sales, will be invaluable to Eden as we accelerate our growth plans by expanding our regulatory and commercial footprint.

Rob’s appointment is considered a key hire within the Company’s previously announced plans to grow its in-house capabilities through the recruitment of high-calibre staff with relevant experience and track records of demonstrable success.”

For further information contact:

Eden Research plc (AIM: EDEN), the AIM-listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries announces that, at the Annual General Meeting (“AGM”) of Eden held yesterday at 1.30pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED, all the resolutions were duly passed.

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global crop protection, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements. 

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company.  To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania and Portugal and Macedonia.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com.

Eden Research plc (AIM: EDEN), the AIM-listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, will hold its AGM today at 1.30pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED.

At the meeting, Eden's Chairman, Lykele van der Broek, will make the following statement:

“Since last year’s AGM Eden has reached some key milestones and made good progress with the commercialisation and regulatory clearance of its products.

At the end of last calendar year, Eden’s commercial partner, Sipcam Oxon SpA (‘Sipcam’), paid €0.9m for the exclusive right to sell Mevalone in ten additional countries, including the US, China and Brazil.

During 2018, sales of Mevalone more than doubled to £1.6m helping Eden to achieve overall revenue of £2.8m. This growth was generated by essentially the same commercial “footprint” that was in place in 2017, which is a good like-for-like comparison reflecting a growing market share and strong product adoption of our first product.

Already this year, Eden’s commercial partner, Eastman Chemical (‘Eastman’), has received authorisation for Eden's nematicide formulation, marketed as Cedroz by Eastman, from the Regulatory Affairs Directorate in Malta. Malta is acting as the zonal rapporteur Member State for the Southern EU agricultural zone and on behalf of a number of EU countries for indoor uses. Additionally, an emergency authorisation has recently been granted in Italy by the Italian Ministry of Agriculture. The granting of this type of authorisation gives an indication as to the need for this type of product in the market and has resulted in the first commercial sales of Cedroz.

It is clear that the world of agchem, whilst inherently conservative, is swiftly undergoing major disruption due to external drivers such as regulatory issues, resistance problems with conventional pesticides, and the ever-increasing cost of the registration of new products. In this environment of turmoil and disruption caused by the removal of important conventional pesticides from global markets at a rate that is troubling for farmers, Eden is well-placed to sustainably and effectively meet many of the current and future needs of growers. Eden’s products align perfectly with the course set for the industry by changing public policy and increasingly challenging regulations, and we aim to ensure that the Company, our shareholders, growers and our commercial partners benefit from the success that this alignment will bring.”

Company presentation

After the conclusion of the formal business of the AGM, Sean Smith, Eden’s Chief Executive Officer will provide a short presentation to investors with an overview of Company progress and strategy. No new material information will be disclosed in the presentation and it will be available on the Company’s website later today.

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global crop protection, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania, Portugal and Macedonia.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com.

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its commercial partner, Eastman Chemical Company (“Eastman”), has made its first sales of Cedroz™ following the recent receipt of “emergency” authorisation by the Italian authorities.

Cedroz, which was initially developed and patented by Eden, is an innovative and natural solution designed to combat plant parasitic nematodes, pests that are known to cause severe damage to crops globally in both open field and greenhouse horticulture, resulting in yield losses and increasing growers costs. Eden produced and supplied Cedroz to Eastman in March this year in anticipation of regulatory clearance in Italy during the course of the 2019 growing season.

Sean Smith, Chief Executive Officer of Eden, said: “We are pleased to see initial sales of Cedroz this early in the year following the derogation in Italy just a few weeks ago. Eastman has seized upon this earlier-than-anticipated opportunity to launch Cedroz in order to fully develop the market for this important product, and Eden has been more than happy to support them in their efforts to move the product to commercial use as quickly as possible.

We look forward to continuing our work with Eastman and to working with growers to combat plant parasitic nematodes with an effective and sustainable solution.”

For further information contact:

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £14m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

Mevalone has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania, Portugal and Macedonia.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com.

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its commercial partner, Eastman Chemical Company (“Eastman”), has received a 120 day “emergency use” authorisation for Eden’s nematicide formulation, marketed as Cedroz™ by Eastman, from the Italian Ministry of Agriculture.  Such “emergency” authorisations are allowed by EU member states when local regulatory authorities judge that they are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives.  During this period, Italy and other member states will continue to process Eastman’s request for the authorised use and sale of Cedroz following Malta’s earlier authorisation.

Cedroz is an innovative and sustainable solution designed to fight plant parasitic nematodes, pests that are known to cause severe damage to crops globally in both open field and greenhouse horticulture, resulting in significant yield losses and increasing growers’ costs.

In line with consumer demand and a policy push for products that support sustainable agriculture with greatly reduced or no pesticide residues, Cedroz is an attractive alternative for farmers looking to fight plant parasitic nematodes in a safer and more sustainable way. Unlike many other products, Cedroz will have no set maximum residue level and a zero-day pre-harvest interval, thereby allowing applications right up to harvest, when required.

As previously announced, Malta has recently authorised the use of Cedroz on a wide range of crops, including cucumbers, courgettes, melons, aubergine, peppers, tomatoes and strawberries marking the initial authorisation for Cedroz in the EU.  Following the authorisation by Malta, the concerned Member States (“cMS”) must grant their individual approvals for the sale and use of Cedroz within their jurisdictions.  The pending approvals will cover Spain and Italy, for outdoor uses and will also cover France, Belgium, the Netherlands and the United Kingdom, as well as Spain and Italy, for professional greenhouse uses.  Once approved, Cedroz will be the first of Eden’s formulations to be sold and used in the United Kingdom, where the company is headquartered.

Sean Smith, Chief Executive Officer of Eden, said: "Following Eden’s initial investment in the formulation and patent protection of this important product, Eastman has invested significant resource over the past three years in the further development of Cedroz, and it is pleasing to see our collective efforts coming to fruition.

“Traditional crop protection products are increasingly coming under threat from global regulatory pressures based upon the potential impact these products may have on the environment. There is significant and increasing demand for biopesticides as alternatives to conventional pesticide treatments due to their health and environmental safety profiles.  We are looking forward to working with Eastman to capitalise on this growing demand and helping them to launch Cedroz in a number of new territories, including the UK.

“The Italian market represents a significant opportunity for Cedroz and, as such, it is great to see the regulatory authorities respond positively by granting this emergency authorisation. This also verifies that  there is a limited number of alternative products available to tackle nematodes in the Italian market and consequently growers need new tools to help control this damaging pest on a range of important high value crops.”

Guy Van Den Bossche, General Manager Crop Protection at Eastman, said: “This 120 day “emergency use” authorisation is a great early opportunity that allows growers to upscale Cedroz in real growing conditions and confirm the numerous successful trials done during the development of the product in Italy as a bigger market looking for alternative sustainable solutions to cope with the growing nematode issue.”

For further information contact:

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company.  To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

Mevalone has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania and Portugal.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com.